25 XP   0   0   10

Kukje Pharma Co Ltd
Buy, Hold or Sell?

Let's analyse Kukje Pharma Co Ltd together

PenkeI guess you are interested in Kukje Pharma Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kukje Pharma Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kukje Pharma Co Ltd

I send you an email if I find something interesting about Kukje Pharma Co Ltd.

Quick analysis of Kukje Pharma Co Ltd (30 sec.)










What can you expect buying and holding a share of Kukje Pharma Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
₩4,171.86
Expected worth in 1 year
₩4,705.70
How sure are you?
65.0%

+ What do you gain per year?

Total Gains per Share
₩533.84
Return On Investment
10.7%

For what price can you sell your share?

Current Price per Share
₩4,995.00
Expected price per share
₩4,165 - ₩8,120
How sure are you?
50%

1. Valuation of Kukje Pharma Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩4,995.00

Intrinsic Value Per Share

₩13,885.47 - ₩16,620.03

Total Value Per Share

₩18,057.33 - ₩20,791.90

2. Growth of Kukje Pharma Co Ltd (5 min.)




Is Kukje Pharma Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$59.4m$50.6m$868.8k1.7%

How much money is Kukje Pharma Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$1.4m$622.5k-$2m-142.3%
Net Profit Margin-6.1%2.7%--

How much money comes from the company's main activities?

3. Financial Health of Kukje Pharma Co Ltd (5 min.)




What can you expect buying and holding a share of Kukje Pharma Co Ltd? (5 min.)

Welcome investor! Kukje Pharma Co Ltd's management wants to use your money to grow the business. In return you get a share of Kukje Pharma Co Ltd.

What can you expect buying and holding a share of Kukje Pharma Co Ltd?

First you should know what it really means to hold a share of Kukje Pharma Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Kukje Pharma Co Ltd is ₩4,995. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kukje Pharma Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kukje Pharma Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩4,171.86. Based on the TTM, the Book Value Change Per Share is ₩133.46 per quarter. Based on the YOY, the Book Value Change Per Share is ₩67.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kukje Pharma Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.010.0%-0.070.0%0.030.0%-0.020.0%0.000.0%
Usd Book Value Change Per Share0.650.0%0.090.0%0.050.0%0.030.0%0.020.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.650.0%0.090.0%0.050.0%0.030.0%0.030.0%
Usd Price Per Share4.14-3.22-3.37-4.04-3.43-
Price to Earnings Ratio-77.44--15.29-6.29-26.34-25.40-
Price-to-Total Gains Ratio6.37-18.07-78.45-143.30-36.05-
Price to Book Ratio1.42-1.26-1.36-1.66-1.44-
Price-to-Total Gains Ratio6.37-18.07-78.45-143.30-36.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.4965
Number of shares286
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.090.03
Usd Total Gains Per Share0.090.03
Gains per Quarter (286 shares)26.728.50
Gains per Year (286 shares)106.8733.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101079723224
2021420446458
3032131169692
404274188128126
5053452510160160
6064163212192194
7074873914224228
8085584616256262
9096295318288296
1001069106020320330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%7.05.00.058.3%12.08.00.060.0%24.010.06.060.0%27.010.07.061.4%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%14.06.00.070.0%26.014.00.065.0%29.015.00.065.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%16.00.024.040.0%16.00.028.036.4%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%14.06.00.070.0%26.014.00.065.0%29.015.00.065.9%

Fundamentals of Kukje Pharma Co Ltd

About Kukje Pharma Co Ltd

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, other ETC products, and other products. Kukje Pharma Co., Ltd. was founded in 1959 and is headquartered in Seongnam-si, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 19:07:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Kukje Pharma Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kukje Pharma Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1.1% means that ₩-0.01 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kukje Pharma Co Ltd:

  • The MRQ is -1.1%. The company is making a loss. -1
  • The TTM is -6.1%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-1.1%TTM-6.1%+5.0%
TTM-6.1%YOY2.7%-8.8%
TTM-6.1%5Y-1.4%-4.6%
5Y-1.4%10Y-0.1%-1.3%
1.1.2. Return on Assets

Shows how efficient Kukje Pharma Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.2% Return on Assets means that Kukje Pharma Co Ltd generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kukje Pharma Co Ltd:

  • The MRQ is -0.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM-1.5%+1.2%
TTM-1.5%YOY0.6%-2.1%
TTM-1.5%5Y-0.3%-1.2%
5Y-0.3%10Y0.0%-0.3%
1.1.3. Return on Equity

Shows how efficient Kukje Pharma Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.5% Return on Equity means Kukje Pharma Co Ltd generated ₩0.00 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kukje Pharma Co Ltd:

  • The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-3.1%+2.6%
TTM-3.1%YOY1.3%-4.4%
TTM-3.1%5Y-0.7%-2.4%
5Y-0.7%10Y-0.1%-0.6%

1.2. Operating Efficiency of Kukje Pharma Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kukje Pharma Co Ltd is operating .

  • Measures how much profit Kukje Pharma Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kukje Pharma Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY4.1%-4.1%
TTM-5Y2.5%-2.5%
5Y2.5%10Y1.8%+0.6%
1.2.2. Operating Ratio

Measures how efficient Kukje Pharma Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.55 means that the operating costs are ₩1.55 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Kukje Pharma Co Ltd:

  • The MRQ is 1.549. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.519. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.549TTM1.519+0.030
TTM1.519YOY1.460+0.059
TTM1.5195Y1.473+0.046
5Y1.47310Y1.230+0.243

1.3. Liquidity of Kukje Pharma Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kukje Pharma Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.92 means the company has ₩0.92 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Kukje Pharma Co Ltd:

  • The MRQ is 0.923. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.966. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.923TTM0.966-0.043
TTM0.966YOY0.989-0.023
TTM0.9665Y1.001-0.034
5Y1.00110Y0.767+0.234
1.3.2. Quick Ratio

Measures if Kukje Pharma Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.34 means the company can pay off ₩0.34 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kukje Pharma Co Ltd:

  • The MRQ is 0.343. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.354. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.343TTM0.354-0.011
TTM0.354YOY0.405-0.051
TTM0.3545Y0.453-0.099
5Y0.45310Y0.708-0.255

1.4. Solvency of Kukje Pharma Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kukje Pharma Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kukje Pharma Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.48 means that Kukje Pharma Co Ltd assets are financed with 48.0% credit (debt) and the remaining percentage (100% - 48.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kukje Pharma Co Ltd:

  • The MRQ is 0.480. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.496. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.480TTM0.496-0.016
TTM0.496YOY0.492+0.004
TTM0.4965Y0.508-0.012
5Y0.50810Y0.502+0.006
1.4.2. Debt to Equity Ratio

Measures if Kukje Pharma Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 92.2% means that company has ₩0.92 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kukje Pharma Co Ltd:

  • The MRQ is 0.922. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.989. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.922TTM0.989-0.067
TTM0.989YOY0.971+0.018
TTM0.9895Y1.036-0.047
5Y1.03610Y1.013+0.023

2. Market Valuation of Kukje Pharma Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Kukje Pharma Co Ltd generates.

  • Above 15 is considered overpriced but always compare Kukje Pharma Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -77.44 means the investor is paying ₩-77.44 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kukje Pharma Co Ltd:

  • The EOD is -65.342. Based on the earnings, the company is expensive. -2
  • The MRQ is -77.442. Based on the earnings, the company is expensive. -2
  • The TTM is -15.286. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-65.342MRQ-77.442+12.100
MRQ-77.442TTM-15.286-62.156
TTM-15.286YOY6.291-21.577
TTM-15.2865Y26.339-41.625
5Y26.33910Y25.402+0.937
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kukje Pharma Co Ltd:

  • The EOD is 60.095. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 71.224. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 28.476. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD60.095MRQ71.224-11.129
MRQ71.224TTM28.476+42.748
TTM28.476YOY-15.591+44.066
TTM28.4765Y5.156+23.320
5Y5.15610Y-4.530+9.686
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kukje Pharma Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.42 means the investor is paying ₩1.42 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Kukje Pharma Co Ltd:

  • The EOD is 1.197. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.419. Based on the equity, the company is underpriced. +1
  • The TTM is 1.263. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.197MRQ1.419-0.222
MRQ1.419TTM1.263+0.156
TTM1.263YOY1.355-0.092
TTM1.2635Y1.658-0.394
5Y1.65810Y1.444+0.214
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kukje Pharma Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--929.650133.460+597%67.421+1279%39.905+2230%32.683+2744%
Book Value Per Share--4171.8643615.532+15%3554.573+17%3466.166+20%3346.194+25%
Current Ratio--0.9230.966-4%0.989-7%1.001-8%0.767+20%
Debt To Asset Ratio--0.4800.496-3%0.492-2%0.508-6%0.502-4%
Debt To Equity Ratio--0.9220.989-7%0.971-5%1.036-11%1.013-9%
Dividend Per Share----0%-0%2.530-100%4.795-100%
Eps---19.111-103.317+441%43.675-144%-22.038+15%-1.782-91%
Free Cash Flow Per Share--20.77931.053-33%64.174-68%16.231+28%67.462-69%
Free Cash Flow To Equity Per Share--20.77931.053-33%-27.583+233%6.527+218%63.173-67%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.850+18%
Intrinsic Value_10Y_max--16620.032--------
Intrinsic Value_10Y_min--13885.469--------
Intrinsic Value_1Y_max--457.217--------
Intrinsic Value_1Y_min--448.388--------
Intrinsic Value_3Y_max--2294.561--------
Intrinsic Value_3Y_min--2171.988--------
Intrinsic Value_5Y_max--5242.054--------
Intrinsic Value_5Y_min--4786.287--------
Market Cap101710687500.000-19%120546000000.00093616593750.000+29%98006658136.875+23%117428128514.438+3%99649968952.781+21%
Net Profit Margin---0.011-0.061+449%0.027-140%-0.014+28%-0.001-94%
Operating Margin----0%0.041-100%0.025-100%0.018-100%
Operating Ratio--1.5491.519+2%1.460+6%1.473+5%1.230+26%
Pb Ratio1.197-19%1.4191.263+12%1.355+5%1.658-14%1.444-2%
Pe Ratio-65.342+16%-77.442-15.286-80%6.291-1331%26.339-394%25.402-405%
Price Per Share4995.000-19%5920.0004597.500+29%4813.096+23%5766.882+3%4893.798+21%
Price To Free Cash Flow Ratio60.095-19%71.22428.476+150%-15.591+122%5.156+1281%-4.530+106%
Price To Total Gains Ratio5.373-19%6.36818.067-65%78.455-92%143.300-96%36.053-82%
Quick Ratio--0.3430.354-3%0.405-15%0.453-24%0.708-52%
Return On Assets---0.002-0.015+520%0.006-140%-0.003+35%0.000-93%
Return On Equity---0.005-0.031+577%0.013-136%-0.007+54%-0.001-85%
Total Gains Per Share--929.650133.460+597%67.421+1279%42.435+2091%37.479+2380%
Usd Book Value--59464701.52051534886.419+15%50665994.495+17%49405870.398+20%47695817.342+25%
Usd Book Value Change Per Share--0.6510.093+597%0.047+1279%0.028+2230%0.023+2744%
Usd Book Value Per Share--2.9202.531+15%2.488+17%2.426+20%2.342+25%
Usd Dividend Per Share----0%-0%0.002-100%0.003-100%
Usd Eps---0.013-0.072+441%0.031-144%-0.015+15%-0.001-91%
Usd Free Cash Flow--296185.148442625.491-33%914723.047-68%231355.438+28%865429.289-66%
Usd Free Cash Flow Per Share--0.0150.022-33%0.045-68%0.011+28%0.047-69%
Usd Free Cash Flow To Equity Per Share--0.0150.022-33%-0.019+233%0.005+218%0.044-67%
Usd Market Cap71197481.250-19%84382200.00065531615.625+29%68604660.696+23%82199689.960+3%69754978.267+21%
Usd Price Per Share3.497-19%4.1443.218+29%3.369+23%4.037+3%3.426+21%
Usd Profit---272403.880-1472657.802+441%622533.356-144%-314121.101+15%-25403.324-91%
Usd Revenue--24707429.82423690220.845+4%22152095.513+12%21812629.457+13%21261743.053+16%
Usd Total Gains Per Share--0.6510.093+597%0.047+1279%0.030+2091%0.026+2380%
 EOD+3 -5MRQTTM+20 -12YOY+16 -175Y+26 -910Y+17 -19

3.2. Fundamental Score

Let's check the fundamental score of Kukje Pharma Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-65.342
Price to Book Ratio (EOD)Between0-11.197
Net Profit Margin (MRQ)Greater than0-0.011
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.343
Current Ratio (MRQ)Greater than10.923
Debt to Asset Ratio (MRQ)Less than10.480
Debt to Equity Ratio (MRQ)Less than10.922
Return on Equity (MRQ)Greater than0.15-0.005
Return on Assets (MRQ)Greater than0.05-0.002
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Kukje Pharma Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.659
Ma 20Greater thanMa 505,649.500
Ma 50Greater thanMa 1005,104.300
Ma 100Greater thanMa 2005,388.100
OpenGreater thanClose4,860.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets163,259,483
Total Liabilities78,309,910
Total Stockholder Equity84,944,087
 As reported
Total Liabilities 78,309,910
Total Stockholder Equity+ 84,944,087
Total Assets = 163,259,483

Assets

Total Assets163,259,483
Total Current Assets55,119,200
Long-term Assets108,140,283
Total Current Assets
Cash And Cash Equivalents 10,589,867
Short-term Investments 42,287
Net Receivables 20,429,244
Inventory 21,243,102
Other Current Assets 1
Total Current Assets  (as reported)55,119,200
Total Current Assets  (calculated)52,304,500
+/- 2,814,700
Long-term Assets
Property Plant Equipment 99,123,972
Intangible Assets 919,292
Long-term Assets Other 0
Long-term Assets  (as reported)108,140,283
Long-term Assets  (calculated)100,043,264
+/- 8,097,019

Liabilities & Shareholders' Equity

Total Current Liabilities59,687,459
Long-term Liabilities18,622,451
Total Stockholder Equity84,944,087
Total Current Liabilities
Short Long Term Debt 30,000,000
Accounts payable 8,563,967
Other Current Liabilities 46,028
Total Current Liabilities  (as reported)59,687,459
Total Current Liabilities  (calculated)38,609,995
+/- 21,077,464
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt662,086
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)18,622,451
Long-term Liabilities  (calculated)662,086
+/- 17,960,365
Total Stockholder Equity
Total Stockholder Equity (as reported)84,944,087
Total Stockholder Equity (calculated)0
+/- 84,944,087
Other
Capital Stock21,159,832
Common Stock Shares Outstanding 20,252
Net Debt 19,410,133
Net Invested Capital 114,944,087
Net Working Capital -4,568,258
Property Plant and Equipment Gross 154,112,698



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
118,749,075
120,055,413
115,980,789
117,430,860
117,599,358
119,668,477
118,821,833
117,508,309
119,666,855
145,900,994
145,545,244
136,643,778
137,753,916
139,390,007
132,031,203
129,455,413
131,346,395
130,086,596
135,958,174
131,646,346
129,837,806
128,090,046
126,934,935
126,234,896
137,123,467
139,717,095
133,504,826
134,593,614
140,490,529
153,387,158
151,187,045
145,625,552
146,187,993
145,432,835
145,160,166
139,783,047
145,914,243
144,981,666
142,698,685
136,592,863
139,386,214
142,377,024
138,538,073
163,259,483
163,259,483138,538,073142,377,024139,386,214136,592,863142,698,685144,981,666145,914,243139,783,047145,160,166145,432,835146,187,993145,625,552151,187,045153,387,158140,490,529134,593,614133,504,826139,717,095137,123,467126,234,896126,934,935128,090,046129,837,806131,646,346135,958,174130,086,596131,346,395129,455,413132,031,203139,390,007137,753,916136,643,778145,545,244145,900,994119,666,855117,508,309118,821,833119,668,477117,599,358117,430,860115,980,789120,055,413118,749,075
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60,437,696
61,665,539
58,772,590
63,757,257
59,537,269
57,227,769
57,422,944
56,176,717
54,559,369
62,475,441
62,219,183
58,258,486
61,135,036
64,823,242
63,866,510
55,035,965
49,940,202
53,691,223
53,158,941
53,547,110
48,197,308
54,731,531
54,494,391
53,097,306
48,535,452
52,028,260
55,832,363
53,648,871
55,119,200
55,119,20053,648,87155,832,36352,028,26048,535,45253,097,30654,494,39154,731,53148,197,30853,547,11053,158,94153,691,22349,940,20255,035,96563,866,51064,823,24261,135,03658,258,48662,219,18362,475,44154,559,36956,176,71757,422,94457,227,76959,537,26963,757,25758,772,59061,665,53960,437,696000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,389,173
3,213,428
1,939,508
2,149,707
2,526,447
3,358,973
5,644,148
5,570,133
3,658,579
1,387,346
2,085,494
1,575,615
7,448,034
10,963,424
5,626,503
2,989,881
4,013,015
4,322,338
4,145,039
7,125,485
7,866,062
11,779,264
12,228,812
9,887,699
5,538,928
8,438,397
12,236,149
10,142,987
10,589,867
10,589,86710,142,98712,236,1498,438,3975,538,9289,887,69912,228,81211,779,2647,866,0627,125,4854,145,0394,322,3384,013,0152,989,8815,626,50310,963,4247,448,0341,575,6152,085,4941,387,3463,658,5795,570,1335,644,1483,358,9732,526,4472,149,7071,939,5083,213,4286,389,173000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,225
2,061,224
3,408
43,361
44,546
0
274,557
3,053,462
3,000,000
3,504,694
3,171,597
2,629,344
2,934,741
2,760,727
6,662,146
228,691
260,424
34,106
40,172
34,362
36,909
27,905
28,985
20,570
20,178
21,005
24,356
35,204
42,287
42,28735,20424,35621,00520,17820,57028,98527,90536,90934,36240,17234,106260,424228,6916,662,1462,760,7272,934,7412,629,3443,171,5973,504,6943,000,0003,053,462274,557044,54643,3613,4082,061,22446,225000000000000000
       Net Receivables 
42,329,823
45,781,643
43,942,394
45,682,315
45,212,625
47,126,738
46,964,879
45,621,559
44,774,525
47,284,942
43,422,466
43,563,229
42,418,876
40,910,644
37,609,497
35,696,541
37,242,757
37,522,254
41,050,340
38,163,259
37,283,841
35,796,628
31,758,686
33,218,122
23,446,481
23,133,769
20,087,271
34,145,694
32,179,100
29,868,088
28,049,260
23,937,137
26,214,500
27,043,596
25,314,883
23,486,302
24,116,375
21,895,465
19,909,525
20,358,679
19,592,096
20,060,827
18,931,454
20,429,244
20,429,24418,931,45420,060,82719,592,09620,358,67919,909,52521,895,46524,116,37523,486,30225,314,88327,043,59626,214,50023,937,13728,049,26029,868,08832,179,10034,145,69420,087,27123,133,76923,446,48133,218,12231,758,68635,796,62837,283,84138,163,25941,050,34037,522,25437,242,75735,696,54137,609,49740,910,64442,418,87643,563,22943,422,46647,284,94244,774,52545,621,55946,964,87947,126,73845,212,62545,682,31543,942,39445,781,64342,329,823
       Other Current Assets 
554,302
289,333
333,603
386,250
382,809
393,821
367,108
462,942
320,106
338,695
368,040
947,570
733,789
652,929
697,014
176,737
186,066
795,785
253,507
723,550
138,355
72,710
340,950
292,238
-1
1
-1
302,437
446,289
611,321
529,286
49,837
763,111
226,637
206,648
244,117
531,098
299,567
597,702
347,292
0
0
1
1
1100347,292597,702299,567531,098244,117206,648226,637763,11149,837529,286611,321446,289302,437-11-1292,238340,95072,710138,355723,550253,507795,785186,066176,737697,014652,929733,789947,570368,040338,695320,106462,942367,108393,821382,809386,250333,603289,333554,302
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,648,026
77,497,912
75,246,340
73,458,578
75,667,287
89,520,648
96,151,080
95,685,350
92,496,770
92,273,893
91,613,056
91,585,738
91,182,712
90,487,276
89,601,378
88,057,411
87,357,954
86,544,661
84,889,203
108,140,283
108,140,28384,889,20386,544,66187,357,95488,057,41189,601,37890,487,27691,182,71291,585,73891,613,05692,273,89392,496,77095,685,35096,151,08089,520,64875,667,28773,458,57875,246,34077,497,91274,648,026000000000000000000000000
       Property Plant Equipment 
39,327,219
38,749,982
37,779,561
37,312,872
37,101,240
37,514,889
36,795,023
36,057,349
35,300,312
62,873,424
62,430,225
61,944,479
61,528,631
61,210,545
59,853,861
60,129,888
60,166,613
59,771,114
60,949,257
60,644,615
60,436,301
60,200,955
60,130,644
61,277,407
62,981,814
65,657,833
65,257,964
64,887,677
67,335,253
81,037,636
85,793,515
86,986,234
83,991,691
83,114,142
82,387,074
81,980,876
81,417,717
80,626,779
79,783,234
78,379,846
77,725,113
77,159,810
75,883,877
99,123,972
99,123,97275,883,87777,159,81077,725,11378,379,84679,783,23480,626,77981,417,71781,980,87682,387,07483,114,14283,991,69186,986,23485,793,51581,037,63667,335,25364,887,67765,257,96465,657,83362,981,81461,277,40760,130,64460,200,95560,436,30160,644,61560,949,25759,771,11460,166,61360,129,88859,853,86161,210,54561,528,63161,944,47962,430,22562,873,42435,300,31236,057,34936,795,02337,514,88937,101,24037,312,87237,779,56138,749,98239,327,219
       Goodwill 
0
0
0
170,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000170,000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,420,474
1,936,676
3,210,960
3,684,350
3,730,010
4,461,928
3,699,807
3,875,618
3,717,338
5,039,781
5,334,330
3,364,941
2,016,200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,016,2003,364,9415,334,3305,039,7813,717,3383,875,6183,699,8074,461,9283,730,0103,684,3503,210,9601,936,6761,420,474000000000000000
       Intangible Assets 
930,257
1,176,372
1,020,620
1,025,083
1,024,571
1,024,085
923,611
761,185
760,763
758,087
757,076
756,081
741,803
840,801
1,223,583
635,875
1,601,565
2,398,595
2,584,842
879,449
2,800,418
1,894,314
1,907,572
823,274
1,818,442
1,764,123
1,709,804
1,677,485
1,623,166
1,568,851
1,514,544
1,492,236
1,437,929
1,448,697
1,390,988
1,333,273
1,275,564
1,235,105
1,176,271
1,125,437
1,066,603
1,007,769
948,936
919,292
919,292948,9361,007,7691,066,6031,125,4371,176,2711,235,1051,275,5641,333,2731,390,9881,448,6971,437,9291,492,2361,514,5441,568,8511,623,1661,677,4851,709,8041,764,1231,818,442823,2741,907,5721,894,3142,800,418879,4492,584,8422,398,5951,601,565635,8751,223,583840,801741,803756,081757,076758,087760,763761,185923,6111,024,0851,024,5711,025,0831,020,6201,176,372930,257
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
724,246
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000010000724,246000000000000000000000000
> Total Liabilities 
63,225,890
63,917,684
60,950,607
59,101,938
60,322,527
62,323,989
60,164,731
66,655,246
68,255,581
70,914,106
69,741,175
68,184,899
68,706,334
70,392,158
63,444,628
61,936,189
63,631,725
62,245,334
67,210,752
63,868,042
61,808,250
60,643,770
58,255,422
57,536,743
66,992,107
76,687,391
69,663,751
73,639,661
74,712,671
78,603,150
75,794,943
75,126,688
74,966,481
74,119,923
73,100,059
71,195,238
75,258,951
73,310,918
69,584,016
62,513,603
64,478,889
73,768,432
72,518,499
78,309,910
78,309,91072,518,49973,768,43264,478,88962,513,60369,584,01673,310,91875,258,95171,195,23873,100,05974,119,92374,966,48175,126,68875,794,94378,603,15074,712,67173,639,66169,663,75176,687,39166,992,10757,536,74358,255,42260,643,77061,808,25063,868,04267,210,75262,245,33463,631,72561,936,18963,444,62870,392,15868,706,33468,184,89969,741,17570,914,10668,255,58166,655,24660,164,73162,323,98960,322,52759,101,93860,950,60763,917,68463,225,890
   > Total Current Liabilities 
57,054,862
58,177,361
45,272,098
31,086,590
31,775,009
34,279,384
38,610,154
55,559,601
56,163,542
54,133,407
39,681,817
32,036,508
30,899,911
33,522,324
41,007,650
49,931,516
48,977,425
48,480,526
53,136,298
50,577,481
50,416,834
48,938,031
47,934,911
48,199,752
55,118,525
64,415,658
54,945,933
59,250,772
56,514,554
58,147,202
54,343,750
55,357,617
54,153,079
54,111,815
54,570,879
54,516,685
57,429,298
56,169,521
52,036,693
47,855,143
48,791,891
58,817,639
57,881,363
59,687,459
59,687,45957,881,36358,817,63948,791,89147,855,14352,036,69356,169,52157,429,29854,516,68554,570,87954,111,81554,153,07955,357,61754,343,75058,147,20256,514,55459,250,77254,945,93364,415,65855,118,52548,199,75247,934,91148,938,03150,416,83450,577,48153,136,29848,480,52648,977,42549,931,51641,007,65033,522,32430,899,91132,036,50839,681,81754,133,40756,163,54255,559,60138,610,15434,279,38431,775,00931,086,59045,272,09858,177,36157,054,862
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,089,798
33,030,000
33,000,162
10,000,000
34,500,000
2,000,000
2,000,000
2,000,000
2,000,000
32,534,082
34,308,682
30,173,844
33,058,916
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000033,058,91630,173,84434,308,68232,534,0822,000,0002,000,0002,000,0002,000,00034,500,00010,000,00033,000,16233,030,00033,089,798000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,089,798
33,030,000
33,000,162
10,000,000
34,500,000
2,000,000
2,000,000
2,000,000
2,000,000
32,456,638
34,308,682
30,173,844
33,058,916
28,000,000
28,000,000
28,000,000
34,000,000
34,000,000
34,000,000
36,000,000
34,000,000
34,000,000
31,000,000
29,000,000
27,000,000
27,000,000
30,000,000
30,000,000
30,000,000
30,000,00030,000,00030,000,00027,000,00027,000,00029,000,00031,000,00034,000,00034,000,00036,000,00034,000,00034,000,00034,000,00028,000,00028,000,00028,000,00033,058,91630,173,84434,308,68232,456,6382,000,0002,000,0002,000,0002,000,00034,500,00010,000,00033,000,16233,030,00033,089,798000000000000000
       Accounts payable 
16,049,614
16,748,053
14,654,121
12,321,930
12,510,609
14,100,511
13,635,521
13,809,875
13,572,333
9,406,613
11,733,476
9,517,020
10,104,728
14,300,943
12,628,370
11,111,465
12,361,512
11,643,881
15,184,192
11,482,686
9,824,442
10,152,359
9,670,067
8,133,910
11,092,745
12,363,818
8,339,842
8,607,640
11,322,599
13,011,626
11,697,654
7,248,121
9,138,759
9,711,776
7,915,128
7,248,969
9,373,989
9,596,883
8,886,529
7,068,443
8,643,217
7,594,074
7,832,360
8,563,967
8,563,9677,832,3607,594,0748,643,2177,068,4438,886,5299,596,8839,373,9897,248,9697,915,1289,711,7769,138,7597,248,12111,697,65413,011,62611,322,5998,607,6408,339,84212,363,81811,092,7458,133,9109,670,06710,152,3599,824,44211,482,68615,184,19211,643,88112,361,51211,111,46512,628,37014,300,94310,104,7289,517,02011,733,4769,406,61313,572,33313,809,87513,635,52114,100,51112,510,60912,321,93014,654,12116,748,05316,049,614
       Other Current Liabilities 
8,144,745
8,804,358
7,624,010
8,211,692
7,865,344
9,160,875
7,652,628
13,382,537
6,735,608
7,935,124
7,877,417
9,158,699
7,713,600
8,153,921
7,307,686
7,730,253
7,585,913
7,836,483
8,952,106
8,594,795
9,592,392
7,985,752
8,459,401
10,008,096
46,237
46,237
46,237
16,196,868
15,803,363
15,720,569
13,228,806
12,655,440
9,507,034
8,896,813
9,151,456
11,791,050
12,552,655
14,030,217
12,636,311
12,151,652
46,158
46,158
46,157
46,028
46,02846,15746,15846,15812,151,65212,636,31114,030,21712,552,65511,791,0509,151,4568,896,8139,507,03412,655,44013,228,80615,720,56915,803,36316,196,86846,23746,23746,23710,008,0968,459,4017,985,7529,592,3928,594,7958,952,1067,836,4837,585,9137,730,2537,307,6868,153,9217,713,6009,158,6997,877,4177,935,1246,735,60813,382,5377,652,6289,160,8757,865,3448,211,6927,624,0108,804,3588,144,745
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,873,582
12,271,734
14,717,818
14,388,889
18,198,117
20,455,947
21,451,193
19,769,071
20,813,402
20,008,108
18,529,180
16,678,553
17,829,652
17,141,397
17,547,323
14,658,460
15,686,998
14,950,793
14,637,136
18,622,451
18,622,45114,637,13614,950,79315,686,99814,658,46017,547,32317,141,39717,829,65216,678,55318,529,18020,008,10820,813,40219,769,07121,451,19320,455,94718,198,11714,388,88914,717,81812,271,73411,873,582000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-33,089,798
-33,030,000
-33,000,162
-10,000,000
-34,500,000
-2,000,000
-2,000,000
-2,000,000
-2,000,000
-31,807,994
-33,648,922
-29,533,638
-32,523,126
1,854,071
1,833,315
2,024,042
2,135,932
2,252,382
2,171,765
2,083,428
1,986,644
2,186,544
2,137,421
1,999,478
1,596,041
1,720,804
1,633,427
1,032,929
662,086
662,0861,032,9291,633,4271,720,8041,596,0411,999,4782,137,4212,186,5441,986,6442,083,4282,171,7652,252,3822,135,9322,024,0421,833,3151,854,071-32,523,126-29,533,638-33,648,922-31,807,994-2,000,000-2,000,000-2,000,000-2,000,000-34,500,000-10,000,000-33,000,162-33,030,000-33,089,798000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
-1
0
1
0
1
0
0
0
0
1
0
0
-1
0
0
0
0
0
0
000000-100100001010-1-1000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
743,917
0
0
0
1,913,900
0
0
0
1,049,488
0
0
0
832,352
0
0
0
615,217
0
0
0
398,081
0
0
0
180,946
0
0
0
0
0000180,946000398,081000615,217000832,3520001,049,4880001,913,900000743,917000000000000000
> Total Stockholder Equity
55,396,360
55,966,325
54,831,857
58,294,767
57,233,829
57,318,274
58,648,019
50,795,397
51,389,421
74,901,627
75,670,392
68,262,793
68,890,995
68,777,360
68,571,563
67,503,624
67,704,036
67,791,555
68,702,902
67,742,810
67,995,330
67,414,854
68,651,038
68,672,406
70,107,064
63,005,781
63,816,474
60,929,114
65,753,339
74,756,868
75,372,846
70,482,457
71,201,433
71,291,977
72,040,400
68,568,062
70,638,780
71,660,920
73,106,321
74,074,073
74,901,417
68,603,883
66,013,421
84,944,087
84,944,08766,013,42168,603,88374,901,41774,074,07373,106,32171,660,92070,638,78068,568,06272,040,40071,291,97771,201,43370,482,45775,372,84674,756,86865,753,33960,929,11463,816,47463,005,78170,107,06468,672,40668,651,03867,414,85467,995,33067,742,81068,702,90267,791,55567,704,03667,503,62468,571,56368,777,36068,890,99568,262,79375,670,39274,901,62751,389,42150,795,39758,648,01957,318,27457,233,82958,294,76754,831,85755,966,32555,396,360
   Common Stock
15,438,450
15,438,450
15,438,450
15,438,450
15,438,450
15,868,708
15,868,708
15,868,708
15,868,708
16,607,318
16,607,318
16,607,318
16,607,318
16,607,318
16,607,318
16,607,318
16,607,318
17,396,596
17,396,596
17,396,596
17,396,596
18,057,107
18,057,107
18,057,107
18,057,107
18,400,520
18,400,520
18,400,520
18,400,520
18,400,520
18,400,520
18,400,520
19,276,090
19,276,090
19,276,090
19,276,090
19,276,090
20,195,149
20,195,149
20,195,149
0
0
0
0
000020,195,14920,195,14920,195,14919,276,09019,276,09019,276,09019,276,09019,276,09018,400,52018,400,52018,400,52018,400,52018,400,52018,400,52018,400,52018,057,10718,057,10718,057,10718,057,10717,396,59617,396,59617,396,59617,396,59616,607,31816,607,31816,607,31816,607,31816,607,31816,607,31816,607,31816,607,31815,868,70815,868,70815,868,70815,868,70815,438,45015,438,45015,438,45015,438,45015,438,450
   Retained Earnings 
19,254,200
19,694,492
18,695,936
0
0
20,803,701
21,988,069
0
14,027,351
15,279,460
14,525,859
0
7,746,462
7,632,827
7,427,030
7,382,516
7,144,009
7,314,212
8,167,836
7,254,177
6,807,962
6,307,758
7,534,652
7,870,638
8,708,698
1,570,718
2,366,653
492,983
6,215,396
6,488,676
7,133,421
3,058,916
3,865,075
3,949,471
4,730,124
1,094,519
3,190,802
4,311,743
5,738,430
6,326,958
7,105,793
807,121
-1,768,182
-3,390,982
-3,390,982-1,768,182807,1217,105,7936,326,9585,738,4304,311,7433,190,8021,094,5194,730,1243,949,4713,865,0753,058,9167,133,4216,488,6766,215,396492,9832,366,6531,570,7188,708,6987,870,6387,534,6526,307,7586,807,9627,254,1778,167,8367,314,2127,144,0097,382,5167,427,0307,632,8277,746,462014,525,85915,279,46014,027,351021,988,06920,803,7010018,695,93619,694,49219,254,200
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-2,436,606-2,436,6060-2,419,202-2,399,700-2,462,847-2,453,650-2,103,293-1,079,866-1,079,866-1,079,866-1,079,866-89,891-1,617,184-1,618,168-1,618,168-1,618,168-1,618,168-1,618,168-1,618,168-1,618,168-1,618,168-1,618,168
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,705,253
41,494,530
40,631,765
40,626,341
40,657,687
39,919,204
40,633,043
40,642,333
40,327,715
40,580,900
40,629,823
40,644,581
39,630,891
37,265,854
47,462,952
45,967,336
46,618,301
46,576,657
46,582,804
46,550,574
46,713,842
46,712,095
46,630,096
46,672,626
47,028,033
0
0
0
0
000047,028,03346,672,62646,630,09646,712,09546,713,84246,550,57446,582,80446,576,65746,618,30145,967,33647,462,95237,265,85439,630,89140,644,58140,629,82340,580,90040,327,71540,642,33340,633,04339,919,20440,657,68740,626,34140,631,76541,494,53040,705,253000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue135,372,691
Cost of Revenue-68,148,048
Gross Profit67,224,64267,224,642
 
Operating Income (+$)
Gross Profit67,224,642
Operating Expense-137,361,833
Operating Income-1,989,143-70,137,191
 
Operating Expense (+$)
Research Development2,645,615
Selling General Administrative43,136,212
Selling And Marketing Expenses0
Operating Expense137,361,83345,781,827
 
Net Interest Income (+$)
Interest Income394,016
Interest Expense-1,439,891
Other Finance Cost-1
Net Interest Income-1,045,876
 
Pretax Income (+$)
Operating Income-1,989,143
Net Interest Income-1,045,876
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-6,680,611-1,989,143
EBIT - interestExpense = -1,439,891
-8,415,187
-6,975,296
Interest Expense1,439,891
Earnings Before Interest and Taxes (EBIT)0-5,240,720
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-6,680,611
Tax Provision-1,734,277
Net Income From Continuing Ops-8,414,888-8,414,888
Net Income-8,415,187
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net01,045,876
 

Technical Analysis of Kukje Pharma Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kukje Pharma Co Ltd. The general trend of Kukje Pharma Co Ltd is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kukje Pharma Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kukje Pharma Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7,170 < 7,900 < 8,120.

The bearish price targets are: 4,365 > 4,170 > 4,165.

Tweet this
Kukje Pharma Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kukje Pharma Co Ltd. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kukje Pharma Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kukje Pharma Co Ltd. The current macd is -82.85321548.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kukje Pharma Co Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kukje Pharma Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kukje Pharma Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kukje Pharma Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartKukje Pharma Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kukje Pharma Co Ltd. The current adx is 26.43.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Kukje Pharma Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Kukje Pharma Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kukje Pharma Co Ltd. The current sar is 5,776.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Kukje Pharma Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kukje Pharma Co Ltd. The current rsi is 43.66. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Kukje Pharma Co Ltd Daily Relative Strength Index (RSI) ChartKukje Pharma Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kukje Pharma Co Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kukje Pharma Co Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Kukje Pharma Co Ltd Daily Stochastic Oscillator ChartKukje Pharma Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kukje Pharma Co Ltd. The current cci is -83.37941807.

Kukje Pharma Co Ltd Daily Commodity Channel Index (CCI) ChartKukje Pharma Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kukje Pharma Co Ltd. The current cmo is -20.90206548.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kukje Pharma Co Ltd Daily Chande Momentum Oscillator (CMO) ChartKukje Pharma Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kukje Pharma Co Ltd. The current willr is -87.88819876.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Kukje Pharma Co Ltd Daily Williams %R ChartKukje Pharma Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kukje Pharma Co Ltd.

Kukje Pharma Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kukje Pharma Co Ltd. The current atr is 336.85.

Kukje Pharma Co Ltd Daily Average True Range (ATR) ChartKukje Pharma Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kukje Pharma Co Ltd. The current obv is 338,960,126.

Kukje Pharma Co Ltd Daily On-Balance Volume (OBV) ChartKukje Pharma Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kukje Pharma Co Ltd. The current mfi is 24.32.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kukje Pharma Co Ltd Daily Money Flow Index (MFI) ChartKukje Pharma Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kukje Pharma Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Kukje Pharma Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kukje Pharma Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.659
Ma 20Greater thanMa 505,649.500
Ma 50Greater thanMa 1005,104.300
Ma 100Greater thanMa 2005,388.100
OpenGreater thanClose4,860.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kukje Pharma Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Kukje Pharma Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kukje Pharma Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kukje Pharma Co Ltd

I send you an email if I find something interesting about Kukje Pharma Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Kukje Pharma Co Ltd.

Receive notifications about Kukje Pharma Co Ltd in your mailbox!